Latest Trials Latest NewsFAQ

Center for Research in Security Prices, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Stem Cell Transplantation for Patients With Multiple Myeloma

Phase 1

Active, not recruiting

Conditions: Myeloma

Interventions: Drug: G-CSF
Drug: Plerixafor
Procedure: Apheresis
Drug: Melphalan
Procedure: Stem cell re-infusion
Device: CliniMACS CD25 microbeads and cell sorter
Drug: Basiliximab

First Posted Date: 2012-02-03

Last Posted Date: 2024-01-29

Lead Sponsor: University of Chicago

Target Recruit Count: 15

Registration Number: NCT01526096

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer

Phase 1

Completed

Conditions: Recurrent Breast Cancer
Male Breast Cancer
Stage IIIA Breast Cancer
Stage IIIB Breast Cancer
Stage IV Breast Cancer
Stage IIIC Breast Cancer

Interventions: Drug: placebo
Drug: mifepristone
Drug: nab-paclitaxel

First Posted Date: 2011-12-15

Last Posted Date: 2018-09-12

Lead Sponsor: University of Chicago

Target Recruit Count: 9

Registration Number: NCT01493310

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸
NorthShore University Health System, Evanston, Illinois, United States

Effects of Allergic Rhinitis on the Nasal/Sinus Microbiome

Completed

Conditions: Allergic Rhinitis

Interventions: Other: Swab of vestibule and middle meatus of nose

First Posted Date: 2011-10-28

Last Posted Date: 2014-03-27

Lead Sponsor: University of Chicago

Target Recruit Count: 40

Registration Number: NCT01461200

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Teaching Use of Respiratory Inhalers (TURI)

Not Applicable

Completed

Conditions: COPD
Asthma

Interventions: Other: Teach-to-Goal Education
Other: Brief Intervention

First Posted Date: 2011-10-20

Last Posted Date: 2019-06-18

Lead Sponsor: University of Chicago

Target Recruit Count: 50

Registration Number: NCT01456494

Locations: 🇺🇸
University of Chicago Medical Center, Chicago, Illinois, United States

The Efficacy of Claritin in Healthy Subjects

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Claritin

First Posted Date: 2011-10-14

Last Posted Date: 2018-03-13

Lead Sponsor: University of Chicago

Target Recruit Count: 340

Registration Number: NCT01451996

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Effectiveness of Interventions to Teach Respiratory Inhaler Technique (E-TRaIN)

Not Applicable

Completed

Conditions: Asthma
Chronic Obstructive Pulmonary Disease (COPD)

Interventions: Behavioral: Brief Intervention
Behavioral: Teach-To-Goal

First Posted Date: 2011-08-31

Last Posted Date: 2019-11-19

Lead Sponsor: University of Chicago

Target Recruit Count: 120

Registration Number: NCT01426581

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy

Recruiting

Conditions: Gastric Cancers

First Posted Date: 2011-08-15

Last Posted Date: 2024-07-31

Lead Sponsor: University of Chicago

Target Recruit Count: 1000

Registration Number: NCT01416714

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Impact of Exenatide on Sleep Duration

Completed

Conditions: Type 2 Diabetes

First Posted Date: 2011-08-15

Last Posted Date: 2023-04-26

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT01416649

Locations: 🇺🇸
The University of Chicago, Chicago, Illinois, United States

Vandetanib in Preventing Head and Neck Cancer in Patients With Precancerous Head and Neck Lesions

Phase 2

Completed

Conditions: Precancerous Condition
Lip and Oral Cavity Squamous Cell Carcinoma
Oral Cavity Verrucous Carcinoma

Interventions: Other: placebo
Drug: vandetanib
Other: immunohistochemistry staining method
Other: laboratory biomarker analysis
Procedure: biopsy
Other: pharmacological study

First Posted Date: 2011-08-11

Last Posted Date: 2021-01-14

Lead Sponsor: University of Chicago

Target Recruit Count: 20

Registration Number: NCT01414426

Locations: 🇺🇸
University of Chicago, Chicago, Illinois, United States

Alemtuzumab on Surrogate Markers of Disease Activity and Repair Using Advanced MRI Measures in Subjects With Relapsing Remitting Multiple Sclerosis

Phase 4

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: Alemtuzumab

First Posted Date: 2011-07-15

Last Posted Date: 2018-12-07

Lead Sponsor: University of Chicago

Target Recruit Count: 8

Registration Number: NCT01395316

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy